Agency: Cordis | Branch: FP7 | Program: CP-TP | Phase: KBBE.2013.3.6-01 | Award Amount: 11.70M | Year: 2013
The Nano3Bio project convenes a consortium of world renowned experts from 8 EU universities, 1 large company, and 14 SME, to develop biotechnological production systems for nanoformulated chitosans. Chitosans, chitin-derived polysaccharides varying in their degree of polymerisation (DP), degree of acetylation (DA), and pattern of acetylation (PA), are among the most versatile and most promising biopolymers, with excellent physico-chemical and material properties, and a wide range of biological functionalities, but their economic potential is far from being exploited due to i) problems with reproducibility of biological activities as todays chitosans are rather poorly defined mixtures, and ii) the threat of allergen contamination from their typical animal origin. The Nano3Bio project will overcome these hurdles to market entry and penetration by producing in vitro and in vivo defined oligo- and polymers with controlled, tailor-made DP, DA, and PA. Genes for chitin synthases, chitin deacetylases, and transglycosylating chitinases/chitosanases will be mined from different (meta)genomic sources and heterologously expressed, the recombinant enzymes characterized and optimized by protein engineering through rational design and molecular evolution, e.g. targeting engineered glycosynthases. These enzymes and genes will be used for in vitro and in vivo biosynthesis in microbial and microalgal systems, focusing on bacteria and diatoms. The bioinspired chitosans will be formulated into biomineralised hydrogels, nanoparticles, nanoscaffolds, etc., to impart novel properties, including by surface nano-imprinting, and will be bench-marked against their conventional counterparts in a variety of cell based assays and routine industrial tests for e.g. cosmetics and pharma markets. The process will be accompanied by comprehensive life cycle assessments including thorough legal landscaping, and by dissemination activities targeted to the scientific community and the general public.
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: NMP-2007-3.1-3 | Award Amount: 19.08M | Year: 2008
iNTeg-Risk is a large-scale integrating project aimed at improving the management of emerging risks in the innovative industry. This will be achieved by building a new risk management paradigm for emerging risks, which is a set of principles supported by a common language, commonly agreed tools & methods and Key Performance Indicators integrated into a single framework. As main impact, it will reduce time-to-market for the lead market EU technologies and promote safety, security, environmental friendliness and social responsibility as a trade-mark of the advanced EU technologies. The project will improve early recognition and monitoring of emerging risks, seek to reduce accidents caused by them (estimated 75 B/year EU27) and decrease reaction times if major accidents involving emerging risks happen. iNTeg-risk will reach its goals by promoting a EU-wide cross-sectorial life-cycle-based integration across all major disciplines, methods and tools as well as through integration of all relevant stakeholders. The project will be initiated from an empirical basis of 17 individual emerging risk issues (Emerging Risk Representative industrial Applications), and generalize their solutions addressing new technologies, products/materials, production and policies. The solutions will be validated in a second application cycle, and the overall solution made available to stakeholders in the form of the iNTeg-Risk platform: a one-stop shop for EU solutions addressing emerging risks. It will feature issues of early recognition and monitoring of emerging risks, communication, governance, pre-standardization, education & training, dissemination, as well as new tools such as Safetypedia, Atlas of Emerging Risks, Reference Library... The project has a solid industry leadership and involves the leading EU R&D institutions. It is coordinated by the European Virtual Institute for Integrated Risk Management, the EEIG guaranteeing the sustainability of the results after the project.
Agency: Cordis | Branch: FP7 | Program: BSG-SME | Phase: SME-1 | Award Amount: 1.33M | Year: 2010
The EU trend towards concentration and intensification of livestock, in particular pig farming, has resulted in increased burdens related to waste management (increased water, soil and air ammonia pollution) as well as increased difficulties to adhere to EU environmental legislation. Consortium SMEs have identified a clear need to find a cost effective, carbon neutral way of eliminating inassimilable ammonia to prevent environmental pollution and reduce costs of waste disposal for the farmers. Most existing manure treatment processes do not eliminate ammonia from the waste. The proposed PLASMANURE project will transform excess ammonia found in pig waste into an environmentally neutral product in a simple, on site, cost-efficient manner, without intervention of sensitive biologic methods. The technology will further enhance existing treatments by facilitating the oxidation of ammonia coming from pig manure into nitrogen gas and water vapour that can be released into the atmosphere, causing no negative environmental impact. This technology will focus solely on the ammonia elimination stage. The commercial object of this proposal is to develop a cost-effective optimized plasma-catalyst reactor for manure wastes that will result in direct economic benefits and improve the competitiveness of consortium partners by reducing costs associated with ammonia fixing and separation strategies (pH control, stripping-scrubbing sequences, etc.) needed in manure treatment. By optimizing steps in waste processing, Plasmanure will also result in savings on processing equipment and time. Plasmanure technology will also significantly reduce the costs associated with regeneration of regions affected by acid rain and eutrophication and, combined with existing treatment systems, will result in new market opportunities, and competitive product differentiation.
Agency: Cordis | Branch: FP7 | Program: CP | Phase: ICT-2011.3.2 | Award Amount: 10.77M | Year: 2012
Microfluidics and lab-on-chip is an enabling technology with great growth potential. The life science industry has come to realise the trends and potential of miniaturisation which already have effected the information and communication industry in the last decades. Combinations of microfluidics, microelectronics and microoptics provide striking opportunities for advancing biomedical research and creating new markets for the medical sciences industry. In terms of economical and ecologically worthwhile processes, complex Micro-Nano Bio Systems (MNBS) have greatest potential to enhance processes for cell-based assays, chemical analytics and medical diagnostics.\nHowever, there are three main challenges for such (MNBS) market to overcome which hamper growth of the market: First, a lack of economical micro-fabrication methods hamper the implementation of lab-on-chip solutions in an industrial scale. Second, inefficient interfaces between laboratory equipment and mircofluidic devices cause a lack of interoperability. Third, there is no integrated manufacturing platform which provides flexible and cheap design and re-design opportunities.\n\nML will overcome these three main challenges by developing a cost efficient production system for new generation MNBS, combining microfluidics, optics and microelectronics. The devices will base on a multi layer concept. The overall function of the smart device will be split in several subfunctions, which can be of fluidic, optical or electronic nature. Multiple foils will transfer the functionality into technical solutions. Economic roll-to-roll processes will be developed for the production of micro fluidic and optic functional layers.\nML will provide a design and manufacturing platform for the production of sophisticated devices which combine microfluidics, optics and microelectronics. ML devices will compact devices with increased performance at lower prices compared to existing MNBS.
Agency: Cordis | Branch: FP7 | Program: CP-TP | Phase: NMP.2011.2.1-1 | Award Amount: 4.94M | Year: 2012
Ceramic composite materials have for many years been considered to show great promise in the repair of musculoskeletal defects. The materials can mimic the structure of bone, and devices made from the materials can be structured to closely match the mechanical requirements of implant sites. In addition, wide ranges of bioactivity are possible, from inert to fully resorbable. Bioceramics have most commonly been used to date in dentistry, and in some orthopaedic applications, e.g. as an injectable paste for vertebroplasty, or as a coating material for metal orthopaedic implants. However, advances in cellular medicine bring great opportunity for significant growth in the bioceramics industry bioceramics and bioceramic composites offer levels of bioactivity which far exceed those available from metal implants, together with combinations of strength and modulus which exceed anything which can be offered by bioactive polymers on their own. Working in tandem with cells, proteins and other biologically active agents (both from the host and introduced) bioceramic composites have the potential to revolutionise many treatments and therapies, giving new, highly effective early stage clinical interventions for conditions where no approach has existed to date. In order to deliver on the potential shown by bioceramic composites the combination of mechanical design, materials, processing, clinical delivery and subsequent biological interaction all have to be understood in an integrated and systematic way. This proposal will address this underlying research and technological challenge in order to develop new bioceramic products for five SME partner companies.
Agency: Cordis | Branch: FP7 | Program: CP-TP | Phase: NMP.2012.1.4-3 | Award Amount: 4.33M | Year: 2013
Knowing the mechanical properties of workpieces and machine-tools also at the nanometer scale is an absolute necessity for an efficient nanoscale production. Current technologies are lacking the flexibility and robustness needed for measuring such key parameters as topography, morphology, roughness, adhesion, or micro- and nano-hardness directly in a production environment. This hinders rapid development cycles and resource efficient process and quality control. The following technology and methodology gaps for addressing these challenges were identified: Efficient disturbance rejection and systems stability; robustness and longevity of probes; short time to data (i.e. high-speed measurements and data handling); and traceability of the measurement. The project aim4np strives at solving this problem by combining measuring techniques developed in nanoscience with novel control techniques from mechatronics and procedures from traceable metrology. Goal and Deliverable The main deliverable will be a fast robotic metrology platform and operational procedures for measuring with nanometer resolution and in a traceable way the topography, morphology, roughness, micro- and nano-hardness, and adhesive properties of large samples in a production environment.
Agency: Cordis | Branch: FP7 | Program: CSA-CA | Phase: Fission-2009-2.3.3 | Award Amount: 718.35K | Year: 2010
HeLiMnet is a project aimed at integrating the R&D efforts going on within and outside Europe, in different areas of investigation In particular it is intended to create a large and strong network for the diffusion of information on the HLM technologies, exploiting the characteristics of both the new information technologies in order to create a virtual space for debates, focus groups and information exchanges and the traditional tools as workshops, seminars, information days etc. It aims, moreover, at rationalize the knowledge through the development of guidelines, protocols and standards, with particular attention to the homogenization of operational procedures in order to have a better control on the quality and comparability of the experimental data obtained in different labs. Finally, one other HeLiMnet goal is the appraisal of the liquid metal technology research area, through the analysis of approaches and activities going on at national and international level in different areas of investigation (fission (LFR, ADS, SFR), neutron spallation targets and fusion), the identification of possible cooperation, the definition of existing gaps and possible future R&D activities to cover these gaps.
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: NMP-2008-2.3-1 | Award Amount: 2.93M | Year: 2010
Heart failure is the end-stage of many cardiovascular diseases, but the leading cause is the presence of a large scar due acute to myocardial infarction. Current therapeutic treatments under development consist in cellular cardiomyoplasty where myocardial cells or stem cells are implanted alone or encapsulated in natural scaffolds (collagens) and grafted onto infarcted ventricles with the hope that cells will contribute to the generation of new myocardial tissue. This approach seems to have a beneficial effect although it is not completely understood and optimized, yet. Thus, the urgent need of better therapeutic platforms is imminent. In view of this, we created a small interdisciplinary consortium (RECATABI) with experts in areas such as material sciences, tissue engineering, stem cell technologies and clinical cardiovascular research. RECATABI will integrate and synergise their capacities in order to obtain a novel clinical platform to regenerate necrotic ischemic tissues after cardiac infarct with a simple one-time patch technology application. The consortium will accomplish this by fabricating nanoscale engineered biomaterials and scaffolds that will match the exact biomechanical and biophysical requirements of the implanted tissue. In addition, the construct may induce rapid vascularization to ensure tissue remodelling and regeneration into a newly functional myocardium. The regenerative capacity of the implants loaded with pre-adapted cells (biomechanically and biophysically trained) will be assessed in small (rodents) and large (sheep) animal models.
Estimation of the uncertainty associated with the results based on the validation of chromatographic analysis procedures: Application to the determination of chlorides by high performance liquid chromatography and of fatty acids by high resolution gas chromatography
Quintela M.,Institute Quimic Of Sarria |
Baguena J.,Institute Quimic Of Sarria |
Gotor G.,Institute Quimic Of Sarria |
Blanco M.J.,Institute Quimic Of Sarria |
Broto F.,Institute Quimic Of Sarria
Journal of Chromatography A | Year: 2012
This article presents a model to calculate the uncertainty associated with an analytical result based on the validation of the analysis procedure. This calculation model is proposed as an alternative to commonly used. bottom-up and. top-down methods. This proposal is very advantageous as the validation of the procedures and the estimation of the uncertainty of the measurement are part of the technical requirements needed in order to obtain the ISO 17025:2005 accreditation. This model has been applied to the determination of chloride by liquid chromatography in lixiviates and in the determination of palmitic acid and stearic acid by gas chromatography in magnesium stearate samples. © 2012 Elsevier B.V..
Institute Quimic Of Sarria | Date: 2012-05-09
Disclosed are nanoparticles comprising a block copolymer and optionally one or more active agent(s), compositions comprising said nanoparticles and methods of preparing said nanoparticles. The block copolymer comprises blocks (i) a first polymer that is a polyester or polyamide and (ii) a second polymer comprising a hydrocarbon chain containing ester or ether bonds with hydroxyl number 10. The active agent(s) may be present within the nanoparticles or on the surfaces of the nanoparticles. The nanoparticles may optionally be associated with a surface-modifying moiety such that they are useful as drug delivery and molecular imaging devices. The surface-modifying moiety may target the nanoparticles to a desired target, cell, tissue or biomarker.